Metastatic Melanoma Market to Grow Significantly by 2032 | Cancer Insight LLC, Elios Therapeutics LLC, Evaxion Biotech A/S, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, InxMed (Shanghai) Co. Ltd, Aivita Biomedical Inc., and others.

{Delhi, India}, To strategically aid Metastatic Melanoma Companies developing drugs for Metastatic Melanoma, DelveInsight launched a report titled “Metastatic Melanoma Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology-based market analysis, providing a roadmap for success in the dynamic landscape of the Metastatic Melanoma Market.

Download a free sample copy of “Metastatic Melanoma Market Report”

Key Highlights from Metastatic Melanoma Market Research Report

• According to the American Cancer Society, melanoma is more prominent in males than females.
• According to the research, In 2020, an estimated 6,850 persons died from melanoma in the United States. For melanoma of the skin, death rates are higher among the middle-aged and elderly. More than 65% of the deaths due to melanoma is between the age group of 55 to 85 years.
• The Metastatic Melanoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Melanoma pipeline products will significantly revolutionize the Metastatic Melanoma market dynamics.
• The leading companies working in the Metastatic Melanoma Market include Cancer Insight LLC, Elios Therapeutics LLC, Evaxion Biotech A/S, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, InxMed (Shanghai) Co. Ltd, Aivita Biomedical Inc., Hoffmann-La Roche, Idera Pharmaceuticals Inc., Iovance Biotherapeutics Inc., Eisai Inc., Biocad, Myrexis Inc., Oncolytics Biotech, Pain Therapeutics, Altor Biosciences, and others.
• Promising Metastatic Melanoma Pipeline Therapies in the various stages of development include TLPLDC Vaccine, EVX-01, Pembrolizumab 25 MG/ML, Nivolumab, IN10018, Cobimetinib, AV-MEL-1, and others.

Metastatic Melanoma Country-based Treatment Analysis

The Metastatic Melanoma treatment market report provides treatment regimens across the 7MM. It will help companies to analyze the practices followed across 7MM, the patient journey, and advances in Metastatic Melanoma therapies that have the potential treatment paradigms and improve patient outcomes.

Melanoma is a common skin cancer that arises from the melanin cells within the upper layer of the skin (epidermis) or from similar cells that may be found in moles (nevi). This type of skin cancer may send down roots into deeper layers of the skin, and some of these microscopic roots may spread (metastasize), causing new tumor growths in vital organs of the body.

Download the report to understand which factors are driving Metastatic Melanoma Epidemiology trends @ Metastatic Melanoma Epidemiology Forecast

Metastatic Melanoma Epidemiology Insights

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Metastatic Melanoma. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the Metastatic Melanoma market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patient’s pools.

Metastatic Melanoma Epidemiology Segmentation

• Metastatic Melanoma Incident Cases
• Metastatic Melanoma Stage-specific Incident Cases
• Metastatic Melanoma Age-specific Incident Cases
• Metastatic Melanoma Type-specific Incident Cases
• Metastatic Melanoma Mutation-specific Incident Cases
• Metastatic Melanoma First-line Treatable Cases

“According to the IO Biotech’s Q2 2023, IO102-IO103 achieved significant enrollment milestone in pivotal Phase III trial ofIO102-IO103 cancer vaccine in advanced melanoma with full enrollment anticipated by the end of 2023”

Metastatic Melanoma Drugs and Companies

• TLPLDC Vaccine: Cancer Insight LLC
• EVX-01: Evaxion Biotech A/S
• Pembrolizumab 25 MG/ML: Merck Sharp & Dhome LLC
• Nivolumab: Novartis Pharmaceuticals
• IN10018: InxMed (Shanghai) Co. Ltd.

Metastatic Melanoma Drugs Uptake

IO102-IO103 (IO Biotech), a combination of two novel immunotherapeutics, IO102 and IO103, which are designed to target IDO and PD-L1 expressing cells, respectively is being evaluated for the patients who suffer from melanoma. Based on findings from the MM1636 Phase I/II clinical study, the FDA granted Breakthrough designation to IO102- IO103 in combination with an anti-PD-1 monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma in December 2020. Currently, the drug is being evaluated in a Phase III (NCT05155254) trial in combination with KEYTRUDA as a first-line therapy in patients with previously untreated, unresectable or metastatic (advanced) melanoma.

Regeneron in collaboration with Bristol Myers Squibb is conducting studies of Vidutolimod (CMP-001) in combination with nivolumab for the treatment of advanced PD-1 refractory, and first-line (PD-1-naïve). In June 2020, the US FDA granted Fast Track designation to CMP-001 in combination with a PD-1 blocking antibody (nivolumab or pembrolizumab) for two development programs, including: initial treatment of patients with unresectable Stage III or Stage IV melanoma to prolong the time to disease progression; and treatment of patients with unresectable or metastatic melanoma refractory to prior anti-PD-1 blockade to improve the overall tumor response rate. Currently, the company is conducting a Phase II/III trial (NCT04695977) in combination with nivolumab in subjects with unresectable or metastatic melanoma and a Phase II trial (NCT04698187) of CMP-001 in combination with nivolumab in anti-PD-1 refractory metastatic melanoma.

Iovance Biotherapeutics is evaluating Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma for neoadjuvant and 2L+ setting. The data from Phase II study continue demonstrated durability and depth of lifileucel TIL therapy response after a one-time treatment, in a difficult to treat patient population with advanced Metastatic melanoma. In May 2023, Iovance Biotherapeutics announced that the US FDA had accepted its Biologics License Application (BLA) for lifileucel for patients with advanced melanoma. The FDA granted lifileucel Priority Review and assigned November 25, 2023 as the target action date for a decision under the Prescription Drug User Fee Act (PDUFA). In September 2023, the FDA extended the new target action date for a decision under the Prescription Drug User Fee Act (PDUFA) to February 24, 2024, but agreed to work with Iovance to expedite the remaining review for a potentially earlier approval date.

LNS8801 (Linnaeus Therapeutics) is an orally bioavailable and highly specific and potent agonist of GPER whose activity is dependent on the expression of GPER. GPER activation by LNS8801 rapidly and durably depletes c-Myc protein levels. In preclinical cancer models, LNS8801 displays potent antitumor activities across a wide range of tumor types, rapidly shrinking tumors and inducing immune memory. In the ongoing clinical study in humans, LNS8801 monotherapy has been safe and well tolerated. Additionally, LNS8801 has demonstrated target engagement, c-Myc protein depletion, and clinical benefit in patients with advanced cancers, and a predictive biomarker has been identified. In January 2023, Linnaeus Therapeutics announced that the FDA has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

To learn more about Metastatic Melanoma Companies working in the treatment market, visit @ Metastatic Melanoma Clinical Trials and Therapeutic Assessment

Metastatic Melanoma Market Insights

The treatment of melanoma focuses on prolonging survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky sites of disease, thereby providing comfort. The treatment landscape of melanoma comprises of immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. However, surgery is also considered as an option for some instances.

Metastatic Melanoma Treatment Market

The metastatic melanoma treatment market has undergone a transformative journey, with immunotherapy and targeted therapies at the forefront of innovation. The integration of combination therapies and ongoing research efforts hold promise for continued advancements in treating metastatic melanoma. As the market evolves, a multidisciplinary approach, including precision medicine and immunotherapy, is likely to shape the future of metastatic melanoma treatment, offering renewed hope for patients and furthering our understanding of cancer biology.

Discover more about therapies set to grab major Metastatic Melanoma Market Share @ Metastatic Melanoma Treatment Market

Scope of the Metastatic Melanoma Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2023-2032
• Metastatic Melanoma Companies- Cancer Insight LLC, Elios Therapeutics LLC, Evaxion Biotech A/S, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, InxMed (Shanghai) Co. Ltd, Aivita Biomedical Inc., Hoffmann-La Roche, Idera Pharmaceuticals Inc., Iovance Biotherapeutics Inc., Eisai Inc., Biocad, Myrexis Inc., Oncolytics Biotech, Pain Therapeutics, Altor Biosciences, and others.
• Metastatic Melanoma Pipeline Therapies- TLPLDC Vaccine, EVX-01, Pembrolizumab 25 MG/ML, Nivolumab, IN10018, Cobimetinib, AV-MEL-1, and others.

Note:-

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Metastatic Melanoma Market Landscape.

Gain Competitive Edge in Indication Market: Understand the current landscape of the Metastatic Melanoma Market, including the competitive environment, key companies developing drugs for Metastatic Melanoma, and their strategies. By analyzing Metastatic Melanoma market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the Metastatic Melanoma Market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Metastatic Melanoma. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the Metastatic Melanoma Market Dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

Plan Roadmap to Success: Through this report, the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Metastatic Melanoma Market with clarity and purpose.

Related Article

BMS’ LAG-3 and PD-1 inhibitor combo all set to fulfill high hopes in melanoma, post receiving priority review by the FDA

Related Reports

Metastatic Melanoma Epidemiology Forecast 2032

DelveInsight's Metastatic Melanoma - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Metastatic Melanoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Metastatic Melanoma Pipeline Insight 2023

Metastatic Melanoma Pipeline Insights, 2023 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.

Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European Bio-Similar landscape. Download Pharma Go-to-Market Case Study!

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/